(85 days)
Not Found
No
The summary describes a comprehensive oncology information system focused on workflow management, data handling, treatment planning support, and verification. There is no mention of AI, ML, or any features that typically utilize these technologies for tasks like image analysis, predictive modeling, or automated decision-making beyond predefined rules and comparisons.
No.
The device is an oncology information system used to manage workflows for treatment planning and delivery; it does not directly treat the patient.
No
The "Intended Use / Indications for Use" section explicitly states, "MOSAIQ® is not intended for use in diagnosis."
Yes
The device is described as a "multi-functional, integrated software suite" and the submission addresses the addition of a software module. While it interacts with hardware (radiotherapy treatment machines), the device itself is presented as a software system for managing workflows and information.
Based on the provided information, MOSAIQ® is NOT an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The intended use clearly states that MOSAIQ® is an oncology information system used to manage workflows for treatment planning and delivery. It supports information flow and is used wherever radiotherapy and/or chemotherapy are prescribed.
- Exclusion of Diagnosis: The document explicitly states: "MOSAIQ® is not intended for use in diagnosis." IVD devices are specifically designed for the in vitro examination of specimens derived from the human body to provide information for diagnosis, monitoring, or screening.
- Device Description: The device description reinforces its role as an electronic oncology management system for managing patient charts, treatment plans, and workflows, not for performing diagnostic tests on patient samples.
- Lack of IVD-Specific Functions: The listed functions (assembling charts, ordering tests, prescribing medications, image management, treatment planning, verification, recording delivered values, stereotactic localization) are related to managing and executing treatment, not performing in vitro diagnostic tests.
While MOSAIQ® can order diagnostic tests, it does not perform the diagnostic testing itself. It is a system for managing the information and workflows associated with oncology treatment.
N/A
Intended Use / Indications for Use
MOSAIQ® is an oncology information system used to manage workflows for treatment planning and delivery. It supports information flow among healthcare facility personnel and can be used wherever radiotherapy and/or chemotherapy are prescribed.
Users can configure MOSAIQ® for Medical Oncology use, Radiation Oncology use, or the two together. It lets users:
- . Assemble electronic patient charts and treatment plans, order diagnostic tests, and prescribe medications.
- Generate and keep medication formulary lists and calculate applicable medication . dosages for medical oncology.
- Import, view, annotate, adjust, enhance, manage and archive images.
- Compare radiation treatment plans and evaluate dose coverage.
- Design leaf plans for operation with radiotherapy treatment machines that have multileaf ● collimators.
- Make sure radiation treatment plans imported from treatment planning systems agree with treatment machine constraints. MOSAIQ® reads actual settings from the treatment machine through the machine communication interface. It compares these settings with predefined values. If a mismatch occurs between the planned values and the actual machine settings, the system warns the user.
- . View reference images to setup treatment. MOSAIQ® refers to predefined settings to help treatment machine setup, and communicates patient and machine setup instructions.
- Record actual delivered radiation values in an electronic chart to track treatment. ●
- Use stereotactic localization to calculate set-up coordinates for treatments. .
MOSAIQ® is not intended for use in diagnosis. Medical oncology dose calculation functions are designed for use with patients 18 years or older only.
Product codes (comma separated list FDA assigned to the subject device)
IYE
Device Description
MOSAIQ is a multi-functional, integrated software suite that forms a comprehensive electronic oncology management system for medical and radiation oncology facilities. For both medical and radiation oncology users, MOSAIQ provides image-enabled electronic patient charting and record management as well as medical transcription and billing functionality. For radiation oncology users, it also includes the ability to import and export radiation treatment plan information, stereotactic localization, treatment plan review, the ability to plan multileaf collimator (MLC) shapes, and verify and record treatment setup and delivery.
This Premarket Notification addresses the addition of the Locate module for Radiation Oncology, which adds stereotactic localization capability to MOSAIQ.
Mentions image processing
- Import, view, annotate, adjust, enhance, manage and archive images.
- Import, view, annotate, manipulate, enhance, manage and archive images
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Medical oncology dose calculation functions are designed for use with patients 18 years or older only.
Intended User / Care Setting
healthcare facility personnel
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Bench testing was performed, as described in Section 16.8. using simulated clinical workflows and ad hoc testing where appropriate, with actual patient data. The product was deemed fit for clinical use.
Verification tests were written and executed to ensure that the system is working as designed. Over 100 test procedures were executed, including tests to verify requirements for new product functionality were met, tests to ensure that risk mitigations function as intended, and regression tests to ensure continued safety and effectiveness of existing functionality. Pass/fail criteria for this testing effort was similar to past testing efforts for the previous versions of MOSAIQ. MOSAIQ passed testing and was deemed safe and effective for its intended use.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical trials were not performed as part of the development of this product. Clinical testing on patients is not advantageous in demonstrating substantial equivalence or safety and effectiveness of the device since testing can be performed such that no human subjects are exposed to risk. Bench testing was performed, as described in Section 16.8. using simulated clinical workflows and ad hoc testing where appropriate, with actual patient data. The product was deemed fit for clinical use.
Verification tests were written and executed to ensure that the system is working as designed. Over 100 test procedures were executed, including tests to verify requirements for new product functionality were met, tests to ensure that risk mitigations function as intended, and regression tests to ensure continued safety and effectiveness of existing functionality. Pass/fail criteria for this testing effort was similar to past testing efforts for the previous versions of MOSAIQ. MOSAIQ passed testing and was deemed safe and effective for its intended use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.5050 Medical charged-particle radiation therapy system.
(a)
Identification. A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories.(b)
Classification. Class II. When intended for use as a quality control system, the film dosimetry system (film scanning system) included as an accessory to the device described in paragraph (a) of this section, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
Image /page/0/Picture/1 description: The image shows the seal of the U.S. Department of Health and Human Services. The seal features a stylized representation of three human profiles facing right, stacked on top of each other. The profiles are rendered in black and appear to be connected by flowing lines at the bottom. The seal is encircled by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
September 5, 2014
IMPAC Medical Systems, Inc. % Kathryn Stinson Regulatory Affairs Specialist 100 Mathilda Place, 5th Floor SUNNYVALE, CA 94086
Re: K141572
Trade/Device Name: MOSAIO Oncology Information System Regulation Number: 21 CFR 892.5050 Regulation Name: Medical charged-particle radiation therapy system Regulatory Class: II Product Code: IYE Dated: June 12, 2014 Received: June 18, 2014
Dear Ms. Stinson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
1
the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Michael O'Harafor
Janine M. Morris Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known): K141572
Device Name: MOSAIQ Oncology Information System
Indications For Use:
MOSAIO® is an oncology information system used to manage workflows for treatment planning and delivery. It supports information flow among healthcare facility personnel and can be used wherever radiotherapy and/or chemotherapy are prescribed.
Users can configure MOSAIQ® for Medical Oncology use, Radiation Oncology use, or the two together. It lets users:
- . Assemble electronic patient charts and treatment plans, order diagnostic tests, and prescribe medications.
- Generate and keep medication formulary lists and calculate applicable medication . dosages for medical oncology.
- Import, view, annotate, adjust, enhance, manage and archive images.
- Compare radiation treatment plans and evaluate dose coverage.
- Design leaf plans for operation with radiotherapy treatment machines that have multileaf ● collimators.
- Make sure radiation treatment plans imported from treatment planning systems agree with treatment machine constraints. MOSAIO® reads actual settings from the treatment machine through the machine communication interface. It compares these settings with predefined values. If a mismatch occurs between the planned values and the actual machine settings, the system warns the user.
- . View reference images to setup treatment. MOSAIQ® refers to predefined settings to help treatment machine setup, and communicates patient and machine setup instructions.
- Record actual delivered radiation values in an electronic chart to track treatment. ●
- Use stereotactic localization to calculate set-up coordinates for treatments. .
MOSAIQ® is not intended for use in diagnosis. Medical oncology dose calculation functions are designed for use with patients 18 years or older only.
| Prescription Use X
(Part 21 CFR 801 Subpart D) | AND/OR | Over-The-Counter Use ______
(21 CFR 807 Subpart C) |
|-------------------------------------------------------------------------------|--------|-------------------------------------------------------|
| (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF
NEEDED) | | |
Concurrence of Center for Devices and Radiological Health (CDRH)
3
June 3, 2014
MOSAIQ Oncology Information System Premarket Notification (510(k)) Summary of Safety and Effectiveness
INTRODUCTION
This document summarizes the safety and effectiveness information contained within the MOSAIQ Oncology Information System 510(k). The Summary of Safety and Effectiveness contains no confidential or trade secret information and is intended for full public disclosure and distribution.
PREMARKET NOTIFICATION INFORMATION
| 1. Product Information: | |
|---|---|
| a. Product Trade Name | MOSAIQ |
| b. Release Version Number | Release 2.60 |
| 2. Classification Information: | |
| a. Classification Name system | Medical charged-particle radiation therapy |
| b. Common/Usual Name | Oncology Information System |
| c. Product Classification | Class II |
| d. Product Code | IYE |
| e. Reference | 21 CFR 892.5050 |
| f. Review Panel | Radiology |
| 3. Establishment Information: | |
| a. Submitter | IMPAC Medical Systems, Inc. |
| b. Submitter Address | 100 Mathilda Place, 5th Floor |
| Sunnyvale, CA 94086 | |
| c. Establishment Number | 2950347 |
| d. Contact | Kathryn Stinson, RA Specialist |
| e. Contact Phone | 314-993-0003 |
| f. Contact Fax | 314-993-0075 |
4
PREDICATE DEVICE INFORMATION
The MOSAIQ Oncology Information System is substantially equivalent to the following devices that the Food and Drug Administration (FDA) has cleared for distribution and are currently being actively marketed in the United States. MOSAIO is substantially equivalent to these products in intended use and safety and effectiveness.
-
- MOSAIQ Oncology Information System IMPAC Medical Systems, Inc. K123230
-
- ERGO++ RTP System IMPAC Medical Systems, Inc. K080601
MOSAIQ INTENDED USE/INDICATIONS FOR USE
MOSAIQ® is an oncology information system used to manage workflows for treatment planning and delivery. It supports information flow among healthcare facility personnel and can be used wherever radiotherapy and/or chemotherapy are prescribed.
Users can configure MOSAIO® for Medical Oncology use. Radiation Oncology use, or the two together. It lets users:
- Assemble electronic patient charts and treatment plans, order diagnostic tests, and ● prescribe medications.
- . Generate and keep medication formulary lists and calculate applicable medication dosages for medical oncology.
- Import, view, annotate, adjust, enhance, manage and archive images. ●
- Compare radiation treatment plans and evaluate dose coverage. ●
- . Design leaf plans for operation with radiotherapy treatment machines that have multileaf collimators.
- Make sure radiation treatment plans imported from treatment planning systems . agree with treatment machine constraints. MOSAIQ® reads actual settings from the treatment machine through the machine communication interface. It compares these settings with predefined values. If a mismatch occurs between the planned values and the actual machine settings, the system warns the user.
- View reference images to setup treatment. MOSAIQ® refers to predefined . settings to help treatment machine setup, and communicates patient and machine setup instructions.
- Record actual delivered radiation values in an electronic chart to track treatment.
- Use stereotactic localization to calculate set-up coordinates for treatments. .
MOSAIQ® is not intended for use in diagnosis. Medical oncology dose calculation functions are designed for use with patients 18 years or older only.
5
DESCRIPTION OF THE PRODUCT
MOSAIQ is a multi-functional, integrated software suite that forms a comprehensive electronic oncology management system for medical and radiation oncology facilities. For both medical and radiation oncology users, MOSAIQ provides image-enabled electronic patient charting and record management as well as medical transcription and billing functionality. For radiation oncology users, it also includes the ability to import and export radiation treatment plan information, stereotactic localization, treatment plan review, the ability to plan multileaf collimator (MLC) shapes, and verify and record treatment setup and delivery.
This Premarket Notification addresses the addition of the Locate module for Radiation Oncology, which adds stereotactic localization capability to MOSAIQ.
LEVEL OF CONCERN
The FDA guidance document entitled "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices," issued May 11, 2005, Table 1, item 4b states, "Does the Software Device control the delivery of potentially harmful energy that could result in death or serious injury, such as radiation treatment systems....."
The record and verify function within MOSAIQ does not directly control the machine that delivers the radiation. However, it does interface with the linear accelerator and is responsible for detecting potential mismatches between planned and actual machine settings and alerting the user. Thus, it is a major level of concern function.
SUMMARY OF CLINICAL TESTING
Clinical trials were not performed as part of the development of this product. Clinical testing on patients is not advantageous in demonstrating substantial equivalence or safety and effectiveness of the device since testing can be performed such that no human subjects are exposed to risk. Bench testing was performed, as described in Section 16.8. using simulated clinical workflows and ad hoc testing where appropriate, with actual patient data. The product was deemed fit for clinical use.
SUMMARY OF NON-CLINICAL TESTING
Verification tests were written and executed to ensure that the system is working as designed. Over 100 test procedures were executed, including tests to verify requirements for new product functionality were met, tests to ensure that risk mitigations function as intended, and regression tests to ensure continued safety and effectiveness of existing functionality. Pass/fail criteria for this testing effort was similar to past testing efforts for
6
the previous versions of MOSAIQ. MOSAIQ passed testing and was deemed safe and effective for its intended use.
7
| Table 11-1: Substantial Equivalence to Legally
Marketed Products | MOSAIQ
with Locate
(new) | MOSAIQ
(Previous)
K123230 | ERGO++ RTP
System
K080601 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|---------------------------------|---------------------------------|
| Ability to define leaf plans for use with radiotherapy
treatment machines equipped with multileaf collimator | Yes | Yes | Yes |
| Ability to import, view, annotate, manipulate, enhance,
manage and archive images | Yes | Yes | Yes |
| Allows users to create, view, and edit geometric
information associated with treatment field definitions,
including the MLC accessory. | Yes | Yes | Yes |
| Checks radiation treatment plans against treatment
machine constraints, provides the capability to notify
clinicians of actions that need to take place prior to
treatment, displays reference images for setup purposes,
and facilitates treatment machine setup according to
predefined settings. | Yes | Yes | No |
| Verification against imported radiation treatment plans | Yes | Yes | No |
| Recording of actual delivered treatment values | Yes | Yes | No |
| Record-only interfaces for appropriate treatment
machines | Yes | Yes | No |
| Integrated electronic patient charting functionality | Yes | Yes | No |
| Administrative functions for practice management (e.g.,
scheduling, billing) | Yes | Yes | No |
| Medical oncology management including care plans,
calculation of medication dosage & dose delivery
tracking | Yes | Yes | No |
| Security features to enable customer HIPAA
compliance | Yes | Yes | Yes |
| DICOM connectivity with compatible systems | Yes | Yes | Yes |
| Software runs on Windows operating system | Yes | Yes | No (Linux) |
| Dose Volume Histogram (DVH) creation and display | Yes | Yes | Yes |
| Displays DVH Statistics | Yes | Yes | Yes |
| Comparison of multiple radiation treatment plans | Yes | Yes | Yes |
| Radiation treatment plan summation and subtraction | Yes | Yes | Yes |
| Includes ability to evaluate brachytherapy & external
beam radiation treatment plans | Yes | Yes | External Beam
Only |
| Isodose & beam display | Yes | Yes | Yes |
| Supports frame-based stereotactic localization | Yes | No | Yes |
| Supports frameless stereotactic localization | No | No | No |
| Support for angiographic images | No | No | Yes |
| Radiation treatment plan optimization & dose
calculation | No | No | Yes |
| Image contouring functionality | No | No | Yes |